Institutional investors purchased a net $5.1 million shares of IMGN during the quarter ended December 2016 and now own 76.29% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CREATIVE PLANNING, INC. Bought 28.7 Thousand shares of ImmunoGen Inc
CREDIT SUISSE AG Bought 4.6 Thousand shares of ImmunoGen Inc
MEDICAL STRATEGY GMBH Bought 2.2 Thousand shares of ImmunoGen Inc